Mallinckrodt Pharmaceuticals to Acquire Questcor for $5.6B

News   Apr 08, 2014

 
Mallinckrodt Pharmaceuticals to Acquire Questcor for $5.6B
 
 
 

RELATED ARTICLES

New Target for Immunotherapy for Solid Tumors?

News

Research from the University of Cincinnati (UC) reveals a potential new target to help T cells (white blood cells) infiltrate certain solid tumors.

READ MORE

E. Coli’s Internal Bomb Offers Chink In Armour

News

Bacteria's internal bomb, the so-called toxin-antitoxin (TA) system that is part of the normal bacterial makeup, may be triggered to make bacteria turn on themselves, providing a valuable target for novel antimicrobial approaches in drug design.

READ MORE

New Cell Therapy Aids Heart Recovery—Without Implanting Cells

News

Columbia biomedical engineers invent innovative technique to help injured hearts regenerate, through therapeutic application of extracellular vesicles secreted by cardiomyocytes derived from human pluripotent stem cells.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE